The peroxisome proliferator- activated receptor-γ (PPARγ) is a clinically validated target for T2DM treatment and its agonists are clinically used to improve insulin resistance and counteract hyperglycemia [3, 4]. The gene discussed is PPARG; the disease is Insulin resistance.